Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Trial of Co-administered AD-2021 and AD-2022 in Primary Hypercholesterolemia and Essential Hypertension
KCT0006283Phase 3Completed
- Sponsor
- Addpharma, Inc.
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of AD-2021, AD-2022 in hypercholesterolemia, essential hypertension, sponsored by Addpharma, Inc.. Started Oct 2020; status: completed.
02
Drugs
AD-2021AD-2022
03
Conditions
hypercholesterolemiaessential hypertension
Beyond the preview
Go deeper on KCT0006283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006283.